s ome observations on the design of early stage clinical trials in the pharmaceutical industry
DESCRIPTION
s ome observations on the design of early stage clinical trials in the pharmaceutical industry. Hans Hockey Biometrics Matters Limited (BML) 13 Nevada Road Hamilton 3216 New Zealand [email protected] IBC, Kobe, Japan, August 2012 EMR-IBS, Tel Aviv, 23 April 2013. - PowerPoint PPT PresentationTRANSCRIPT
![Page 1: s ome observations on the design of early stage clinical trials in the pharmaceutical industry](https://reader036.vdocuments.mx/reader036/viewer/2022062816/56814aa2550346895db7b41a/html5/thumbnails/1.jpg)
SOME OBSERVATIONS ON THE
DESIGN OF EARLY STAGE CLINICAL TRIALS IN THE
PHARMACEUTICAL INDUSTRY
Hans HockeyBiometrics Matters Limited (BML)
13 Nevada RoadHamilton 3216New Zealand
[email protected], Kobe, Japan, August 2012
EMR-IBS, Tel Aviv, 23 April 2013 1
![Page 2: s ome observations on the design of early stage clinical trials in the pharmaceutical industry](https://reader036.vdocuments.mx/reader036/viewer/2022062816/56814aa2550346895db7b41a/html5/thumbnails/2.jpg)
Structure of talk
2
![Page 3: s ome observations on the design of early stage clinical trials in the pharmaceutical industry](https://reader036.vdocuments.mx/reader036/viewer/2022062816/56814aa2550346895db7b41a/html5/thumbnails/3.jpg)
Structure of talk• There is no structure!
3
![Page 4: s ome observations on the design of early stage clinical trials in the pharmaceutical industry](https://reader036.vdocuments.mx/reader036/viewer/2022062816/56814aa2550346895db7b41a/html5/thumbnails/4.jpg)
Five Case Studies1) Two doses plus placebo2) “Factorial” dose escalation and food effect3) 3-treatment, 3-period cross-over design4) Escalating dose study with placebo substitution
plus 5) Augmented placebo insertion and food effect
4
![Page 5: s ome observations on the design of early stage clinical trials in the pharmaceutical industry](https://reader036.vdocuments.mx/reader036/viewer/2022062816/56814aa2550346895db7b41a/html5/thumbnails/5.jpg)
5
Take-home points1. Use contrasts that are orthogonal, and are models, not
tests2. Design programs to include more combined studies,
including factorial and similar designs3. Don’t worry about ‘imbalance’ 4. Practical matters can matter more than statistical issues5. In cross-over designs, never ever fit Sequence6. Use mixed, not fixed, models for maximum information
extraction
![Page 6: s ome observations on the design of early stage clinical trials in the pharmaceutical industry](https://reader036.vdocuments.mx/reader036/viewer/2022062816/56814aa2550346895db7b41a/html5/thumbnails/6.jpg)
6
Take-home point 11. Use contrasts that are orthogonal, and are models, not
tests. 2. Design programs to include more combined studies,
including factorial and similar designs3. Don’t worry about ‘imbalance’ 4. Practical matters can matter more than statistical issues5. In cross-over designs, never ever fit Sequence6. Use mixed, not fixed, models for maximum information
extraction
![Page 7: s ome observations on the design of early stage clinical trials in the pharmaceutical industry](https://reader036.vdocuments.mx/reader036/viewer/2022062816/56814aa2550346895db7b41a/html5/thumbnails/7.jpg)
7
Treatment5 mg 10 mg Placebo
Case Study 1
![Page 8: s ome observations on the design of early stage clinical trials in the pharmaceutical industry](https://reader036.vdocuments.mx/reader036/viewer/2022062816/56814aa2550346895db7b41a/html5/thumbnails/8.jpg)
8
TreatmentContrast 5 mg 10 mg Placebo10 v placebo 0 1 -15 v placebo 1 0 -1
Case Study 1
![Page 9: s ome observations on the design of early stage clinical trials in the pharmaceutical industry](https://reader036.vdocuments.mx/reader036/viewer/2022062816/56814aa2550346895db7b41a/html5/thumbnails/9.jpg)
9
TreatmentContrast 5 mg 10 mg Placebo10 v placebo 0 1 -15 v placebo 1 0 -1
Dose (mg)Contrast 0 5 10Linear -1 0 1Quadratic -1 2 -1
Case Study 1
![Page 10: s ome observations on the design of early stage clinical trials in the pharmaceutical industry](https://reader036.vdocuments.mx/reader036/viewer/2022062816/56814aa2550346895db7b41a/html5/thumbnails/10.jpg)
10
TreatmentContrast 5 mg 10 mg Placebo10 v placebo 0 1 -15 v placebo 1 0 -1
1 1 2Dose (mg)
Contrast 0 5 10Linear -1 0 1Quadratic -1 2 -1
2 2 2
Case Study 1
![Page 11: s ome observations on the design of early stage clinical trials in the pharmaceutical industry](https://reader036.vdocuments.mx/reader036/viewer/2022062816/56814aa2550346895db7b41a/html5/thumbnails/11.jpg)
11
TreatmentContrast 5 mg 10 mg Placebo10 v placebo 0 1 -15 v placebo 1 0 -1
Dose (mg)Contrast 0 5 10Linear -1 0 1Quadratic -1 2 -1
A modeller, not a tester,would prefer even more dose levels
Case Study 1
![Page 12: s ome observations on the design of early stage clinical trials in the pharmaceutical industry](https://reader036.vdocuments.mx/reader036/viewer/2022062816/56814aa2550346895db7b41a/html5/thumbnails/12.jpg)
12
![Page 13: s ome observations on the design of early stage clinical trials in the pharmaceutical industry](https://reader036.vdocuments.mx/reader036/viewer/2022062816/56814aa2550346895db7b41a/html5/thumbnails/13.jpg)
13
![Page 14: s ome observations on the design of early stage clinical trials in the pharmaceutical industry](https://reader036.vdocuments.mx/reader036/viewer/2022062816/56814aa2550346895db7b41a/html5/thumbnails/14.jpg)
14
Take-home point 21. Use contrasts that are orthogonal, and are models, not tests2. Design programs to include more combined studies,
including factorial and similar designs3. Don’t worry about ‘imbalance’ 4. Practical matters can matter more than statistical issues5. In cross-over designs, never ever fit Sequence6. Use mixed, not fixed, models for maximum information
extraction
![Page 15: s ome observations on the design of early stage clinical trials in the pharmaceutical industry](https://reader036.vdocuments.mx/reader036/viewer/2022062816/56814aa2550346895db7b41a/html5/thumbnails/15.jpg)
A typical Phase 1 drug development program list of
studies
Over 50 studies, many are escalating doses or 2x2 crossover designs
15
![Page 16: s ome observations on the design of early stage clinical trials in the pharmaceutical industry](https://reader036.vdocuments.mx/reader036/viewer/2022062816/56814aa2550346895db7b41a/html5/thumbnails/16.jpg)
29 studies with drug plasma concentrations and liver function tests (LFTs)
202 Safety, toleration and PK of single dose escalating oral solution study 203 Compare PK of oral solution and capsule formulation in fasted state 204 Safety, Toleration and PK of single escalating capsule dose study 205 Safety, Toleration and PK of oral SD followed by 10 day oral MD 206 Safety, Toleration and PK of single IV escalating dose 207 Safety, Toleration and PK of single IV escalating dose 208 Compare PK of 200mg capsule dose in fed and fasted states 209 Safety, Toleration and PK of single IV dose followed by 10 day multiple IV 210 PK, Safety and Toleration after oral admin & effect of XYZ on Prednisolone 213 Safety, Toleration and PK of single IV escalating dose 214 Safety, Toleration and PK of single IV dose followed by 10 day multiple IV 217 Compare PK of 200mg oral solution dose in fed and fasted states 222 Compare PK of multiple oral solution dose in fed and fasted states 224 Compare multiple dose bioequivalence of commercial tablet v research capsule 228 Effect of Rifamycins on the PK of XYZ study 229 Cimetidine/ranitidine interaction on PK of XYZ study 230 Multiple dose IV-oral switch over 231 XYZ Visual Electrophysiological Study 232 Pivotal BE study 233 Effect of Phenytoin on XYZ Study 237 Renal Impairment Study 238 Hepatic Insufficiency Study 240 Protease Inhibitor Study 243 Azithromycin Interaction Study 245 Capsule vs tablet bioequivalence study 247 Omeprazole Interaction Study 248 BE Oral Suspension versus new Commercial Tablet Study 250 Young/Elderly Male/Female Study 1005 BE Clinical Tablet v Commercial Tablet/Food Interaction Study
16
![Page 17: s ome observations on the design of early stage clinical trials in the pharmaceutical industry](https://reader036.vdocuments.mx/reader036/viewer/2022062816/56814aa2550346895db7b41a/html5/thumbnails/17.jpg)
26 studies excluded - no LFTs or no XYZ drug alone 001 Tacrolimus Study 201 SD 216 Compare Safety, Toleration and PK of 200mg dose given IV and orally 220 Absorption, Metabolism and Excretion of single oral and single IV dose 225 Toleration, safety of ABC versus placebo 226 Toleration, Safety & PK of IV XYZ with ABC 227 Safety, Toleration & PK of IV XYZ with ABC. 234 Warfarin Interaction study 235 Cyclosporin Interaction Study 236 Digoxin interaction 239 Repeat Warfarin Study 241 XYZ on Phenytoin Study 242 Genotype/phenotype 244 XYZ on Indinovir Study 249 IV Paediatric SD Study 1007 IV Paediatric MD Study 1009 Tacrolimus Interaction Study 1012 Hepatic Impairment Study 1013 Omeprazole Study 1016 Summary (renal impairment) Study JP-501 Oral SD Study JP-502 Intravenous SD Study JP-503 Oral MD Study JP-504 IV MD Study JP-505 Oral SD Genotype Study JP-506 IV SD Genotype
17
![Page 18: s ome observations on the design of early stage clinical trials in the pharmaceutical industry](https://reader036.vdocuments.mx/reader036/viewer/2022062816/56814aa2550346895db7b41a/html5/thumbnails/18.jpg)
Combining studiesRonald Fisher argued in 1926 that "complex" designs (such as factorial designs) were more efficient than studying one factor at a time.Fisher wrote,"No aphorism is more frequently repeated in connection with field trials, than that we must ask Nature few questions, or, ideally, one question, at a time. The writer is convinced that this view is wholly mistaken."Nature, he suggests, will best respond to "a logical and carefully thought out questionnaire".
A factorial design allows the effect of several factors and even interactions between them to be determined with the same number of trials as are necessary to determine any one of the effects by itself with the same degree of accuracy. (Wikipedia) 18
![Page 19: s ome observations on the design of early stage clinical trials in the pharmaceutical industry](https://reader036.vdocuments.mx/reader036/viewer/2022062816/56814aa2550346895db7b41a/html5/thumbnails/19.jpg)
Protocols with drug plasma concentrations and liver function tests (LFTs)
202 Safety, toleration and PK of single dose escalating oral solution study 203 Compare PK of oral solution and capsule formulation in fasted state 204 Safety, Toleration and PK of single escalating capsule dose study 205 Safety, Toleration and PK of oral SD followed by 10 day oral MD 206 Safety, Toleration and PK of single IV escalating dose 207 Safety, Toleration and PK of single IV escalating dose 208 Compare PK of 200mg capsule dose in fed and fasted states 209 Safety, Toleration and PK of single IV dose followed by 10 day multiple IV 210 PK, Safety and Toleration after oral admin & effect of XYZ on Prednisolone 213 Safety, Toleration and PK of single IV escalating dose 214 Safety, Toleration and PK of single IV dose followed by 10 day multiple IV 217 Compare PK of 200mg oral solution dose in fed and fasted states 222 Compare PK of multiple oral solution dose in fed and fasted states 224 Compare multiple dose bioequivalence of commercial tablet v research capsule 228 Effect of Rifamycins on the PK of XYZ study 229 Cimetidine/ranitidine interaction on PK of XYZ study 230 Multiple dose IV-oral switch over 231 XYZ Visual Electrophysiological Study 232 Pivotal BE study 233 Effect of Phenytoin on XYZ Study 237 Renal Impairment Study 238 Hepatic Insufficiency Study 240 Protease Inhibitor Study 243 Azithromycin Interaction Study 245 Capsule vs tablet bioequivalence study 247 Omeprazole Interaction Study 248 BE Oral Suspension versus new Commercial Tablet Study 250 Young/Elderly Male/Female Study 1005 BE Clinical Tablet v Commercial Tablet/Food Interaction Study
19
![Page 20: s ome observations on the design of early stage clinical trials in the pharmaceutical industry](https://reader036.vdocuments.mx/reader036/viewer/2022062816/56814aa2550346895db7b41a/html5/thumbnails/20.jpg)
Case Study 2
20
Combining studies (part 1)
![Page 21: s ome observations on the design of early stage clinical trials in the pharmaceutical industry](https://reader036.vdocuments.mx/reader036/viewer/2022062816/56814aa2550346895db7b41a/html5/thumbnails/21.jpg)
•Three doses by two food regimes. Use all 6 combinations? Both food regimes at all 3 doses
A Phase 1 PK studyDesign 1
Cohorts SubjectsPeriod
1 2 3 4
1
1-4 150 fasted
150 fed
5-8 150 fed 150 fasted
2
9-12 300 fasted
300 fed
13-16 300 fed 300 fasted
3
17-20 600 fasted
600 fed
21-24 600 fed 600 fasted
Fed v fasted always a 2x2 crossoverToo long! (7-day washout three times)
21
![Page 22: s ome observations on the design of early stage clinical trials in the pharmaceutical industry](https://reader036.vdocuments.mx/reader036/viewer/2022062816/56814aa2550346895db7b41a/html5/thumbnails/22.jpg)
•Three doses by two food regimes. Use all 6 combinations? Both food regimes at all 3 doses
A Phase 1 PK studyDesign 2
Cohorts SubjectsPeriod
1 2 3 4
1
1-4 150 fasted
150 fed
5-8 150 fed 150 fasted
2
9-12 300 fasted
300 fed
13-16 300 fed 300 fasted
3
17-20 600 fasted
600 fed
21-24 600 fed 600 fasted
22
![Page 23: s ome observations on the design of early stage clinical trials in the pharmaceutical industry](https://reader036.vdocuments.mx/reader036/viewer/2022062816/56814aa2550346895db7b41a/html5/thumbnails/23.jpg)
•Three doses by two food regimes. Use all 6 combinations? Both food regimes at all 3 doses
A Phase 1 PK studyDesign 2
Cohorts SubjectsPeriod
1 2 3 4
11-4 150
fasted5-8
2
9-12 300 fasted
300 fed
13-16 300 fed 300 fasted
317-20 600
fasted21-24
23
![Page 24: s ome observations on the design of early stage clinical trials in the pharmaceutical industry](https://reader036.vdocuments.mx/reader036/viewer/2022062816/56814aa2550346895db7b41a/html5/thumbnails/24.jpg)
•Three doses by two food regimes. Use all 6 combinations? Both food regimes at all 3 doses
A Phase 1 PK studyDesign 3
Cohorts SubjectsPeriod
1 2 3 4
1 1-12150 fasted
213-18
300 fasted
300 fed
19-24300 fed 300
fasted
1 1-12600 fasted
24
![Page 25: s ome observations on the design of early stage clinical trials in the pharmaceutical industry](https://reader036.vdocuments.mx/reader036/viewer/2022062816/56814aa2550346895db7b41a/html5/thumbnails/25.jpg)
A Phase 1 PK study – Design 3
4, not 6, treatments (6 not 12 cells)Only one washout period
Safe escalationWhat assumptions? Two analyses? NO!
25
![Page 26: s ome observations on the design of early stage clinical trials in the pharmaceutical industry](https://reader036.vdocuments.mx/reader036/viewer/2022062816/56814aa2550346895db7b41a/html5/thumbnails/26.jpg)
Combining studies (part 2)
26
![Page 27: s ome observations on the design of early stage clinical trials in the pharmaceutical industry](https://reader036.vdocuments.mx/reader036/viewer/2022062816/56814aa2550346895db7b41a/html5/thumbnails/27.jpg)
Protocols with drug plasma concentrations and liver function tests (LFTs)
202 Safety, toleration and PK of single dose escalating oral solution study 203 Compare PK of oral solution and capsule formulation in fasted state 204 Safety, Toleration and PK of single escalating capsule dose study 205 Safety, Toleration and PK of oral SD followed by 10 day oral MD 206 Safety, Toleration and PK of single IV escalating dose 207 Safety, Toleration and PK of single IV escalating dose 208 Compare PK of 200mg capsule dose in fed and fasted states 209 Safety, Toleration and PK of single IV dose followed by 10 day multiple IV 210 PK, Safety and Toleration after oral admin & effect of XYZ on Prednisolone 213 Safety, Toleration and PK of single IV escalating dose 214 Safety, Toleration and PK of single IV dose followed by 10 day multiple IV 217 Compare PK of 200mg oral solution dose in fed and fasted states 222 Compare PK of multiple oral solution dose in fed and fasted states 224 Compare multiple dose bioequivalence of commercial tablet v research capsule 228 Effect of Rifamycins on the PK of XYZ study 229 Cimetidine/ranitidine interaction on PK of XYZ study 230 Multiple dose IV-oral switch over 231 XYZ Visual Electrophysiological Study 232 Pivotal BE study 233 Effect of Phenytoin on XYZ Study 237 Renal Impairment Study 238 Hepatic Insufficiency Study 240 Protease Inhibitor Study 243 Azithromycin Interaction Study 245 Capsule vs tablet bioequivalence study 247 Omeprazole Interaction Study 248 BE Oral Suspension versus new Commercial Tablet Study 250 Young/Elderly Male/Female Study 1005 BE Clinical Tablet v Commercial Tablet/Food Interaction Study
27
![Page 28: s ome observations on the design of early stage clinical trials in the pharmaceutical industry](https://reader036.vdocuments.mx/reader036/viewer/2022062816/56814aa2550346895db7b41a/html5/thumbnails/28.jpg)
Case Study 3
Capsule v tablet&
Fed v fast for capsules
28
![Page 29: s ome observations on the design of early stage clinical trials in the pharmaceutical industry](https://reader036.vdocuments.mx/reader036/viewer/2022062816/56814aa2550346895db7b41a/html5/thumbnails/29.jpg)
29
Bioequivalence
Food
effe
ct
A B
C
![Page 30: s ome observations on the design of early stage clinical trials in the pharmaceutical industry](https://reader036.vdocuments.mx/reader036/viewer/2022062816/56814aa2550346895db7b41a/html5/thumbnails/30.jpg)
Protocols with drug plasma concentrations and liver function tests (LFTs)
202 Safety, toleration and PK of single dose escalating oral solution study 203 Compare PK of oral solution and capsule formulation in fasted state 204 Safety, Toleration and PK of single escalating capsule dose study 205 Safety, Toleration and PK of oral SD followed by 10 day oral MD 206 Safety, Toleration and PK of single IV escalating dose 207 Safety, Toleration and PK of single IV escalating dose 208 Compare PK of 200mg capsule dose in fed and fasted states 209 Safety, Toleration and PK of single IV dose followed by 10 day multiple IV 210 PK, Safety and Toleration after oral admin & effect of XYZ on Prednisolone 213 Safety, Toleration and PK of single IV escalating dose 214 Safety, Toleration and PK of single IV dose followed by 10 day multiple IV 217 Compare PK of 200mg oral solution dose in fed and fasted states 222 Compare PK of multiple oral solution dose in fed and fasted states 224 Compare multiple dose bioequivalence of commercial tablet v research capsule 228 Effect of Rifamycins on the PK of XYZ study 229 Cimetidine/ranitidine interaction on PK of XYZ study 230 Multiple dose IV-oral switch over 231 XYZ Visual Electrophysiological Study 232 Pivotal BE study 233 Effect of Phenytoin on XYZ Study 237 Renal Impairment Study 238 Hepatic Insufficiency Study 240 Protease Inhibitor Study 243 Azithromycin Interaction Study 245 Capsule vs tablet bioequivalence study 247 Omeprazole Interaction Study 248 BE Oral Suspension versus new Commercial Tablet Study 250 Young/Elderly Male/Female Study 1005 BE Clinical Tablet v Commercial Tablet/Food Interaction Study
30
![Page 31: s ome observations on the design of early stage clinical trials in the pharmaceutical industry](https://reader036.vdocuments.mx/reader036/viewer/2022062816/56814aa2550346895db7b41a/html5/thumbnails/31.jpg)
31
Formulation effect (1 v 2)
Food
effe
ct (A
v B
)
A1 A2
B2B1
![Page 32: s ome observations on the design of early stage clinical trials in the pharmaceutical industry](https://reader036.vdocuments.mx/reader036/viewer/2022062816/56814aa2550346895db7b41a/html5/thumbnails/32.jpg)
NOT a Case Study
Not seen by me anyhow
32
![Page 33: s ome observations on the design of early stage clinical trials in the pharmaceutical industry](https://reader036.vdocuments.mx/reader036/viewer/2022062816/56814aa2550346895db7b41a/html5/thumbnails/33.jpg)
33
Take-home point 31. Use contrasts that are orthogonal, and are models, not tests2. Design programs to include more combined studies,
including factorial and similar designs3. Don’t worry about ‘imbalance’ 4. Practical matters can matter more than statistical issues5. In cross-over designs, never ever fit Sequence6. Use mixed, not fixed, models for maximum information
extraction
![Page 34: s ome observations on the design of early stage clinical trials in the pharmaceutical industry](https://reader036.vdocuments.mx/reader036/viewer/2022062816/56814aa2550346895db7b41a/html5/thumbnails/34.jpg)
34
Take-home point 3• Use contrasts that are orthogonal, and are models, not tests• Design programs to include more combined studies,
including factorial and similar designs• Not every PK crossover subject needs a placebo • Practical matters can matter more than statistical issues• In cross-over designs, never ever fit Sequence• Use mixed, not fixed, models for maximum information
extraction
![Page 35: s ome observations on the design of early stage clinical trials in the pharmaceutical industry](https://reader036.vdocuments.mx/reader036/viewer/2022062816/56814aa2550346895db7b41a/html5/thumbnails/35.jpg)
Design: This is a single-blind, placebo-controlled, randomised, “cross-over”, single-dose escalation study in which the toleration, safety and pharmacokinetics of XYZ-123,456 will be investigated.
Both ‘cross-over’ and escalation? Two groups or cohorts, 8 each 35
Case Study 4
![Page 36: s ome observations on the design of early stage clinical trials in the pharmaceutical industry](https://reader036.vdocuments.mx/reader036/viewer/2022062816/56814aa2550346895db7b41a/html5/thumbnails/36.jpg)
Subjects Week 1 Week 3 Week 5 Week 7
1&2 Placebo 1 5 20
3&4 1 Placebo 5 20
5&6 1 5 Placebo 20
7&8 1 5 20 Placebo
Group A doses (mg) over time
8 subjects per dose, 8 per Placebo(Same pattern for Group B doses, but 2.5, 10 & 40 mg)
36
![Page 37: s ome observations on the design of early stage clinical trials in the pharmaceutical industry](https://reader036.vdocuments.mx/reader036/viewer/2022062816/56814aa2550346895db7b41a/html5/thumbnails/37.jpg)
Subjects Week 1 Week 3 Week 5 Week 7
1&2 Placebo 1 5 20
3&4 1 Placebo 5 20
5&6 1 5 Placebo 20
7&8 1 5 20 Placebo
Placebo insertion design8 subjects per dose, 8 per Placebo(Same pattern for Group B doses, but 2.5, 10 & 40 mg)
Placebo insertion
37
![Page 38: s ome observations on the design of early stage clinical trials in the pharmaceutical industry](https://reader036.vdocuments.mx/reader036/viewer/2022062816/56814aa2550346895db7b41a/html5/thumbnails/38.jpg)
Subjects Week 1 Week 3 Week 5
1&2 Placebo 5 20
3&4 1 Placebo 20
5&6 1 5 Placebo
Placebo substitution
4 subjects per dose, all 6 per Placebo(Placebo is of least interest for PK, but needed for safety comparisons)
38
![Page 39: s ome observations on the design of early stage clinical trials in the pharmaceutical industry](https://reader036.vdocuments.mx/reader036/viewer/2022062816/56814aa2550346895db7b41a/html5/thumbnails/39.jpg)
Subjects Week 1 Week 3 Week 5
1&2 Placebo 5 20
3&4 1 Placebo 20
5&6 1 5 Placebo
7&8 1 5 20
Why notPlacebo substitution plus!
6 subjects per dose, all 6 per Placebo(Placebo is of least interest for PK, but needed for safety comparisons)
6 per treatment!39
![Page 40: s ome observations on the design of early stage clinical trials in the pharmaceutical industry](https://reader036.vdocuments.mx/reader036/viewer/2022062816/56814aa2550346895db7b41a/html5/thumbnails/40.jpg)
Subjects Week 1 Week 3 Week 5
1&2 Placebo 5 20
3&4 1 Placebo 20
5&6 1 5 Placebo
7&8 1 5 20
“¾ placebo substitution”
Embrace imbalance!
40
![Page 41: s ome observations on the design of early stage clinical trials in the pharmaceutical industry](https://reader036.vdocuments.mx/reader036/viewer/2022062816/56814aa2550346895db7b41a/html5/thumbnails/41.jpg)
Subjects Week 1 Week 3 Week 5 ABCD drop
BIBD
1&2 0 5 20 B ACD
3&4 1 0 20 C BAD
5&6 1 5 0 D BCA
7&8 1 5 20 A BCD
¾ placebo substitution
Embrace imbalance!(but it isn’t unbalanced! – it’s a BIBD)
41
![Page 42: s ome observations on the design of early stage clinical trials in the pharmaceutical industry](https://reader036.vdocuments.mx/reader036/viewer/2022062816/56814aa2550346895db7b41a/html5/thumbnails/42.jpg)
42
Take-home point 41. Use contrasts that are orthogonal, and are models, not tests2. Design programs to include more combined studies,
including factorial and similar designs3. Don’t worry about ‘imbalance’ 4. Practical matters can matter more than statistical issues5. In cross-over designs, never ever fit Sequence6. Use mixed, not fixed, models for maximum information
extraction
![Page 43: s ome observations on the design of early stage clinical trials in the pharmaceutical industry](https://reader036.vdocuments.mx/reader036/viewer/2022062816/56814aa2550346895db7b41a/html5/thumbnails/43.jpg)
Case Study 5
Still don’t worry about imbalance (it also is a BIBD, but plus extra replications of non-placebo sequences)
Do worry about practical issues
(in this case, not sure if 10, 11 or 12 pre-screened subjects will turn up on Day 1, and less on Day 2)
43
![Page 44: s ome observations on the design of early stage clinical trials in the pharmaceutical industry](https://reader036.vdocuments.mx/reader036/viewer/2022062816/56814aa2550346895db7b41a/html5/thumbnails/44.jpg)
Subject Day Dose per dayor First Second First Second
Sequence AM PM AM PM1 E0 E2 A4 A8 2 12
2 A0 A2 E4 E8 2 12
3 E2 E0 A4 A8 2 12
4 A2 A0 E4 E8 2 12
5 E2 E4 A0 A8 6 8
6 A2 A4 E0 E8 6 8
7 E2 E4 A8 A0 6 8
8 A2 A4 E8 E0 6 8
9 E2 E4 A8 A8 6 16
10 A2 A4 E8 E8 6 16
11 E2 E4 A8 A8 6 16
12 A2 A4 E8 E8 6 16
Augmented insertion design for 12 subjects over 4 sessions in 2 days
Ex = Food (fEd) with x capsules Ax = Fasted (fAst) with x capsules
(from final protocol) 44
![Page 45: s ome observations on the design of early stage clinical trials in the pharmaceutical industry](https://reader036.vdocuments.mx/reader036/viewer/2022062816/56814aa2550346895db7b41a/html5/thumbnails/45.jpg)
Practical Design Issues•The design includes placebo insertion such that placebo occurs twice in each of 4 sessions, with double blinding. Each subject has exposure to each active dose, with subjects 9-12 receiving the maximum of two 8-capsule sessions in the one day, after having been exposed to 4 capsules the previous test day. Total exposure ranges from 2 to 16 capsules per day per subject.
•The design is robust to not having all planned 12 subjects available as there is double replication of the sequences 9 and 10 (sequences 11 and 12). Random allocation of sequences to subjects will be arranged such that if there is a shortfall of 1 or 2 subjects then sequence 12 and then 11 will not be allocated. If there is a further shortfall (very unlikely) then all missing Day 1 subjects will be replaced.
•All sequences/subjects include the highest dose on Day 2, so given that 10 to 12 subjects completed Day 1, there is no imperative to replace subjects if up to 2 do not attend Day 2. If the Day 2 discontinuation rate is higher though, then consideration will again be given to subject replacement.
45
![Page 46: s ome observations on the design of early stage clinical trials in the pharmaceutical industry](https://reader036.vdocuments.mx/reader036/viewer/2022062816/56814aa2550346895db7b41a/html5/thumbnails/46.jpg)
46
Take-home point 51. Use contrasts that are orthogonal, and are models, not tests2. Design programs to include more combined studies,
including factorial and similar designs3. Don’t worry about ‘imbalance’ 4. Practical matters can matter more than statistical issues5. In cross-over designs, never ever fit Sequence6. Use mixed, not fixed, models for maximum information
extraction
![Page 47: s ome observations on the design of early stage clinical trials in the pharmaceutical industry](https://reader036.vdocuments.mx/reader036/viewer/2022062816/56814aa2550346895db7b41a/html5/thumbnails/47.jpg)
Advantages of cross-oversUsing within subject variation gives increased precision and power
Lower costs (usually extra subjects more expensive than extra periods)
47
![Page 48: s ome observations on the design of early stage clinical trials in the pharmaceutical industry](https://reader036.vdocuments.mx/reader036/viewer/2022062816/56814aa2550346895db7b41a/html5/thumbnails/48.jpg)
Advantages of cross-oversUsing within subject variation gives increased precision and power
Lower costs
Sequence, carryover and treatment.period are all aliased
Disadvantage of 2x2 cross-overs
48
![Page 49: s ome observations on the design of early stage clinical trials in the pharmaceutical industry](https://reader036.vdocuments.mx/reader036/viewer/2022062816/56814aa2550346895db7b41a/html5/thumbnails/49.jpg)
2x2 cross-over ANOVA table (12 subjects)d.f.
Subjects Sequence 1 Between subject error 10Total 11Periods within subjects Treatment 1 Period 1Within subject error 10Total 12TOTAL 23
49
![Page 50: s ome observations on the design of early stage clinical trials in the pharmaceutical industry](https://reader036.vdocuments.mx/reader036/viewer/2022062816/56814aa2550346895db7b41a/html5/thumbnails/50.jpg)
2x2 cross-over ANOVA table (12 subjects)d.f.
Subjects Carryover 1 Between subject error 10Total 11Periods within subjects Treatment 1 Period 1Within subject error 10Total 12TOTAL 23
50
![Page 51: s ome observations on the design of early stage clinical trials in the pharmaceutical industry](https://reader036.vdocuments.mx/reader036/viewer/2022062816/56814aa2550346895db7b41a/html5/thumbnails/51.jpg)
2x2 cross-over ANOVA table (12 subjects)d.f.
Subjects Treatment.Period 1 Between subject error 10Total 11Periods within subjects Treatment 1 Period 1Within subject error 10Total 12TOTAL 23
51
![Page 52: s ome observations on the design of early stage clinical trials in the pharmaceutical industry](https://reader036.vdocuments.mx/reader036/viewer/2022062816/56814aa2550346895db7b41a/html5/thumbnails/52.jpg)
2x2 cross-over ANOVA table (12 subjects)d.f.
Subjects Sequence 1 Between subject error 9Total 10Periods within subjects Treatment 1 Period 1Within subject error 10Total 12TOTAL 23
52
![Page 53: s ome observations on the design of early stage clinical trials in the pharmaceutical industry](https://reader036.vdocuments.mx/reader036/viewer/2022062816/56814aa2550346895db7b41a/html5/thumbnails/53.jpg)
2x2 cross-over ANOVA table (12 subjects)d.f.
Subjects Sequence 1 Between subject error 9Total 10Periods within subjects Treatment 1 Sequence.Treatment 1Within subject error 10Total 12TOTAL 23
53
![Page 54: s ome observations on the design of early stage clinical trials in the pharmaceutical industry](https://reader036.vdocuments.mx/reader036/viewer/2022062816/56814aa2550346895db7b41a/html5/thumbnails/54.jpg)
My personal preference!d.f.
Subjects Treatment.Period 1 Between subject error 10Total 11Periods within subjects Treatment 1 Period 1Within subject error 10Total 12TOTAL 23
54
![Page 55: s ome observations on the design of early stage clinical trials in the pharmaceutical industry](https://reader036.vdocuments.mx/reader036/viewer/2022062816/56814aa2550346895db7b41a/html5/thumbnails/55.jpg)
55
Take-home point 61. Use contrasts that are orthogonal, and are models, not tests2. Design programs to include more combined studies,
including factorial and similar designs3. Don’t worry about ‘imbalance’ 4. Practical matters can matter more than statistical issues5. In cross-over designs, never ever fit Sequence6. Use mixed, not fixed, models for maximum information
extraction
![Page 56: s ome observations on the design of early stage clinical trials in the pharmaceutical industry](https://reader036.vdocuments.mx/reader036/viewer/2022062816/56814aa2550346895db7b41a/html5/thumbnails/56.jpg)
ReferencesAny of the classic design texts of the 1950s, such as:
• Cochran and Cox (1950)• Kempthorne (1952)• Cox (1958)• Quenouille (1958)• and even Fisher (1935) and Yates (1937)!
56
![Page 57: s ome observations on the design of early stage clinical trials in the pharmaceutical industry](https://reader036.vdocuments.mx/reader036/viewer/2022062816/56814aa2550346895db7b41a/html5/thumbnails/57.jpg)
References (cont’d)
57
![Page 58: s ome observations on the design of early stage clinical trials in the pharmaceutical industry](https://reader036.vdocuments.mx/reader036/viewer/2022062816/56814aa2550346895db7b41a/html5/thumbnails/58.jpg)
Thank you for your attention!
This presentation has been brought to you by:
58
![Page 59: s ome observations on the design of early stage clinical trials in the pharmaceutical industry](https://reader036.vdocuments.mx/reader036/viewer/2022062816/56814aa2550346895db7b41a/html5/thumbnails/59.jpg)
Thank you for your attention!
This presentation has been brought to you by:
59